How effective is the targeted drug gilitinib (Segatan) in treating leukemia?

Leukemia is a serious hematological malignancy, and Gilitinib (Gilteritinib) is a targeted therapy drug targeting FLT3 mutations in leukemia. The following will be combined with clinical trial data to evaluate the efficacy of giritinib in the treatment of leukemia.

1. Clinical Trial Overview:

Giritinib's efficacy comes primarily from the results of clinical trials, including multiple studies in patients with relapsed or refractory AML (acute myeloid leukemia). Here is an overview of some important clinical trials:

ADMIRAL trial: A Phase II/III trial evaluating the efficacy and safety of giritinib in patients with relapsed or refractory AML.

NAVIGATORTrial: A Phase II trial investigating the efficacy and safety of giritinib in untreated patients with AML.

2. Effectiveness evaluation indicators:

In these clinical trials, efficacy evaluation is usually based on the following indicators:

Complete remission rate (CR) and complete remission rate including incomplete recovery of platelets and insufficient megakaryocytes (CRi): whether the white blood cells, bone marrow hematopoietic function, platelets and other indicators in the patient's blood have returned to normal.

Survival period: Including overall survival (OS) and progression-free survival (PFS) to evaluate the impact of treatment on patient survival time and disease progression.

3. Clinical trial results:

According to the latest clinical trial data, giritinib has shown significant efficacy in the treatment of patients with relapsed or refractoryAML:

In theADMIRAL trial, the CR/CRi rate in the geritinib treatment group reached 34 .0%, while the CR/CRi rate in the standard chemotherapy group was only 15.3%. This suggests that AML patients in the geritinib group were more likely to achieve complete remission.

In addition, the ADMIRAL trial also showed that the median progression-free survival (PFS) of the geritinib treatment group was significantly prolonged to 4.6 months, while the standard chemotherapy group's PFS was only 0.9 months. This shows that giritinib treatment can effectively prolong the time to disease progression in patients.

As for survival, although the ADMIRAL trial has not yet reported final data on overall survival (OS), the OS of the geritinib treatment group has shown a certain growth trend, which provides patients with a longer chance of survival.

In addition, data from the NAVIGATOR trial also showed the potential efficacy of giritinib in untreated AML patients, but the trial has not yet published final results.

4. Security assessment:

In clinical trials, the main adverse reactions of giritinib include nausea, vomiting, diarrhea, fatigue, headache, fever and other mild to moderate adverse reactions. In addition, there are reports that giritinib may cause serious adverse reactions such as abnormal liver function and prolonged QT interval, but the incidence of these adverse reactions in clinical trials is low.

According to clinical trial data, giritinib, as a targeted therapy drug targeting FLT3 mutations, has shown significant efficacy in the treatment of relapsed or refractory AML patients. It can improve patients' complete response rate, prolong progression-free survival, and is expected to improve overall survival. Although giritinib may cause some adverse effects, most are mild to moderate and can be managed with appropriate management and monitoring. In summary, giritinib provides an effective and relatively safe treatment option for patients with relapsed or refractory AML.